ACSS2 upregulation enhances neuronal resilience to aging and tau-associated neurodegeneration
Abstract
Epigenetic mechanisms, including histone acetylation, regulate learning and memory and underlie Alzheimer’s disease and related dementia (ADRD). Acetyl-CoA synthetase 2 (ACSS2), an enzyme generating acetyl-CoA, locally regulates histone acetylation and gene expression in neuronal nuclei. This regulatory mechanism may be a promising target for therapeutic intervention in neurodegenerative diseases. Previously, we showed that systemic ACSS2 knockout mice, although largely normal in physiology, exhibit memory deficits. Here, we investigated whether increasing ACSS2 levels could protect neurons against disease and age-associated cognitive decline. Given the role of tau in ADRD, we used primary hippocampal neurons that mimic the sporadic development of tau pathology and the P301S transgenic mouse model for tau-induced memory decline. Our results show that ACSS2 upregulation mitigates tau-induced transcriptional alterations, enhances neuronal resilience against tau pathology, improves long-term potentiation, and ameliorates memory deficits. Additionally, boosting histone acetylation through ACSS2 countered age-related memory decline. These findings indicate that increasing ACSS2 is highly effective in countering age- and tau-induced transcriptome changes, preserving elevated levels of synaptic genes, and safeguarding synaptic integrity. These findings position ACSS2 as a key epigenetic regulator of cognitive aging and ADRD, highlighting its potential for targeted therapeutics to enhance brain resilience and function.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (17)
Naemeh Pourshafie
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine
Desi C. Alexander
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine
Hong Xu
Institute of Nuclear and New Energy Technology
Kechun Yang
Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania
Greg Donahue
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine
Xue Lei
Cancer Genome and Epigenetics Program, Sanford Burnham Prebys Medical Discovery Institute
Shuo Zhang
Oksana Shcherbakova
Department of Biology, School of Arts and Sciences, University of Pennsylvania
Connor Hogan
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine
Michael Gilbert
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine
Kevt’her Hoxha
Lesley Chaboub
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine
Virginia M-Y Lee
Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine
Peter D. Adams
John A. Dani
Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania
Nancy M. Bonini
Department of Biology, School of Arts and Sciences, University of Pennsylvania
Shelley L. Berger
Epigenetics Institute, University of Pennsylvania Perelman School of Medicine